抑制MCT1可以重塑瘤免疫微环境,从而增强癌症免疫疗法
Yipeng Zhang1, Chun Liu1, Fuxin Han1
1Department of Bio-therapeutic, the First Medical Center, Chinese PLA General Hospital (Medical School of Chinese PLA) Beijing China.
单碳酸盐载体1 (MCT1) 推动抑制瘤微环境 (TIME),阻碍癌症免疫疗法. 抑制MCT1可以重编程TIME,增强抗瘤免疫力,促进瘤回归.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 癌症免疫疗法,如免疫检查点阻塞 (ICB),由于免疫抑制性瘤免疫微环境 (TIME),显示出有限的持久反应.
- 在时间内确定关键调节者对于提高治疗疗效至关重要.
研究的目的:
- 调查单碳酸盐载体1 (MCT1) 在塑造时间的作用及其对ICB治疗反应的影响.
- 评估MCT1作为癌症免疫治疗的潜在生物标志物和治疗标.
主要方法:
- 全癌症患者队列分析以评估MCT1表达及其与临床结果的相关性.
- 使用ex vivo共同培养模型和in vivo小鼠癌症模型 (MC38和LLC) 的实验验证.
- 药理上抑制MCT1,以评估其对免疫细胞功能和瘤生长的影响.
主要成果:
- 在时间内,MCT1在恶性和髓状细胞中升级调节,与生存率差和ICB反应降低相关.
- 瘤细胞和巨细胞通过MCT1-介导的乳酸摄取抑制CD8+T细胞激活和细胞毒性.
- 通过MCT1吸收乳酸会诱导IL-10的产生,从而导致CD8+T细胞的抑制.
- 在小鼠模型中药理性MCT1抑制逆转了免疫抑制,增强了CD8+T细胞的透和功能,并导致瘤回归.
结论:
- MCT1在产生免疫抑制的时间和限制癌症免疫疗法的有效性方面发挥着重要作用.
- MCT1是预测治疗反应的潜在泛癌生物标志物.
- 向MCT1是一种有前途的治疗策略,可以增强抗瘤免疫力,改善癌症免疫治疗患者的结果.
更多相关视频
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
Published on: June 7, 2018
08:24Measuring Bone Remodeling and Recreating the Tumor-Bone Microenvironment Using Calvaria Co-culture and Histomorphometry
Published on: March 14, 2020
相关概念视频
07:46Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
08:32Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:24Measuring Bone Remodeling and Recreating the Tumor-Bone Microenvironment Using Calvaria Co-culture and Histomorphometry
11:00Visualization, Quantification, and Mapping of Immune Cell Populations in the Tumor Microenvironment
06:32Multiplex Immunohistochemical Analysis of the Spatial Immune Cell Landscape of the Tumor Microenvironment
10:35An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses
